NASDAQ:DWTX Dogwood Therapeutics Q2 2026 Earnings Report $1.36 -0.07 (-4.90%) Closing price 04:00 PM EasternExtended Trading$1.39 +0.03 (+2.28%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dogwood Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.14Beat/MissMissed by -$0.20One Year Ago EPSN/ADogwood Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADogwood Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:30AM ETUpcoming EarningsDogwood Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dogwood Therapeutics Earnings HeadlinesDogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest UpdateSeptember 18, 2026 | americanbankingnews.comDogwood Therapeutics Stock Price HistorySeptember 15, 2026 | investing.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 25 at 1:00 AM | Base Camp Trading (Ad)Dogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due NovemberSeptember 14, 2026 | rttnews.comDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialSeptember 14, 2026 | globenewswire.comBiotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In FocusSeptember 8, 2026 | rttnews.comSee More Dogwood Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email. Email Address About Dogwood TherapeuticsDogwood Therapeutics (NASDAQ:DWTX). is a clinical-stage biotechnology company focused on developing treatments for diseases associated with neuroinflammation and viral-related immune dysfunction. The company’s research programs are aimed at conditions with limited therapeutic options, including fibromyalgia and symptoms associated with long COVID. Dogwood’s lead investigational product, IMC-1, is a fixed-dose combination of the antiviral drug famciclovir and the anti-inflammatory medicine celecoxib. The company has evaluated IMC-1 in clinical studies for fibromyalgia and is pursuing additional development of the therapy for chronic pain and related conditions. Its pipeline has also included programs directed at post-viral illnesses. The company was formerly known as Virios Therapeutics and changed its name to Dogwood Therapeutics as part of a broader strategic repositioning. Dogwood is headquartered in the United States and conducts its development activities through clinical research and collaborations. The company’s products remain investigational and have not been approved for commercial use in the indications under study.View Dogwood Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
